Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

B-CELLS > Dendritic Cells > Flashcards

Dendritic Cells Flashcards

1
Q

What are the three subsets of DCs?

A

Convention, plasmacytoid and innflamatory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are properties of Convention DCs?

A

Located at body surfaces and secondary Lymphoid tissues
Bring pathogenic material to draining LNs
Activate Naive T-cell responce

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are properties of palsmacytoid DCs?

A

Circulate in blood periphery
Recruited to inflammation sites
Have immunomodulatory role
Produce Type 1 Interferon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are properties of Inflammatory DCs

A

Not found in steady state, only during Inflammation
Monocyte Derived
Increase antigen presentation during inflammation
Re-activate Memory T-cells in non-lymphoid tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Markers for cDC1s human and mouse

Role of cDC1

A

Human: CD141, XCR1, CLEC9A, CADM1.
Mouse: CD103/CD8, XCR1, CLEC9A, CADM1

Role: Cross presentation, production of IL-12 + INF gamma, TLR3 expression, Th1/Th2 generation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Markers for cDC2s in humans and mouse

Role of cDC2

A

Human: CD1c, CD11b, SIRP alpha
Mouse: CD24, CD11B, SIRP alpha

Role: DC4 T- Cell responce, IL-1B, IL-6, IL-23 production,
Expression of all TLR except TLR3 in mice and TLR9 in humans, Th2 and Th17 generation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Where are Conventional and Plasmatoid DCs derived from?

A

Common Dendritic Progenitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Where are Inflammatory DCs derived from?

A

Monocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the Process of a DC immune responce?

A

DCs in pheripheral tissues pick up antigens and express them on MHCs
DCs then become mature and migrate to Draining lymph nodes via the lymphatic vessels
Present antigens to T-cells in lymph nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Whats the differences between mature and immature DCs?

A

Immature - high phagocytosis, Low MHC expression and low co-stimulatory molecules, Low CCR7
Mature: Low phagocytosis, high MHC expression and co-stimulatory molecules and high CCR7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What causes DC maturation?

A 
PAMPS:
Bacterial LPS (detected by TLR4) viral dsRNA (TLR3), Cytokines (TNF alpha and IL-1) and CD40 ligands
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How can you generate DCs from peripheral blood?

A

Isolate CD14 monocytes,
Subject them to IL-4 and GM-CSF (6days) to get an immature DC
Subject them to PAMPs, TNFalpha, IL-1beta 24 hours to get mature DC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the fate of naive Th Cells based on the three signals 1,2 and 3?

A

Signal 1: MHC II expression of antigen to T-cell receptor leads to T-cell activation
Signal 2: CD80/CD26 on APC interact with T-cell CD28, this promotes T-Cell survival, IL-2 production and clonal expansion
Signal 3: APC secrete cytokines, this polarieses T-Cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What cytokine signals produce which Th Cell responce?

What Do these Th cell responses target?

A

IFNgamma - Th1 - Intracellular pathogens, virusus, mycobacterium, activation of macrophages
IL-4- Th2- Extracellular pathogens, helminths,Aid B-cells
1l-17-Th17-Bacteria/fungi (surface tissues recruit neutrophils).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What type of T-Cell responce can DCs trigger in cancer and autoimmune immunotherapy?

A

Effector T-cells - cancer

Tregs - Autoimmuntiy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How can DCs be isolated?

A

cd14+ monocytesm, DC generation, DC antigen loading,
Antigen presentation to T-cells
Maturation state of DCs determines T-Cell response

17
Q

Differecne between immature, semi mature and mature DCs in terms of MHC II, CD80/86, IL-12/IL-6 and TGF beta

A

Immature: MHC II + , CD80/86 - , IL-12/IL-6 - , TGFbeta -
Semi- Mature: MCH II + + , CD80/86 + , IL-12/IL-6 - , TGFbeta ++
Mature : MHC II ++, CD80/86 ++, IL12-IL-6 ++ , TGFbeta +

18
Q

Why use DCs for cancer therapy?

A

DC have ability to remove rare events
Other surgeries/ radio and chemotherapy dont always remove residual cancer cells which can re-occur. DC can clean up these residual cancer cells.
DCs non-toxic and target heterogenous tumors
can have multiple antigen targets and epitope spreading

19
Q

Negative of DCs for cancer therpay

A

Not good at removing bulky tumors

20
Q

Goals of DC based cancer therapy

A

1) Cancer specifc T-cell expansion
2) T-cells with appropriate Effector function
3) T-cells migrate to relevent tumor tissues

21
Q

Problems of DC cancer therapy?

A

No pro-innflamtory signals in cancers (eg no TLR ligands)
Tumors produce suppressive factors ie IL-10 TGFbeta which can lead to DC dyfunction
Cancer patients - expansion and hyperactivation of Tregs

22
Q

Desired DC features for cancer therapy

A

High MHC II/Co-stimulatory factors
High IL-12 to induce CTL and Th1
High CCR7 so DC migrate to lymph nodes
Attraction of desired immune cells - NK cells, CTL and CTH but avoid Tregs by appropriate chemokine profile eg high CCL5,CXCL10,CCL22
Resistant to supression - Final maturation

23
Q

3rd Generation DC cancer therapy

A

1st decribed by Radomski et al.,
CD14 monocyte isoloation, treat with IL-4 and GM-CSF, Which produces immature DCs. Treat with TNF alpha IL-1 INFgamma/alpha and Poly I:C to stimulate TLR3
Called it alphaDC1

24
Q

What was AlphaDC1s profile?

What are proplems with 3rd Gen DC cancer therpay?

A

MHC II +++, CD80/86+++ , CCR7+++, IL-12+++, CCL5/CXXL10 +++

Problems: Monocyte derived, so dont migrate well to lymph nodes (aprox 4%)

25
Q

4th Gen DC cancer therapy

Problems with it

A

Same as 3rd gen but used blood plasmacytoid or conventional DCs. This means no culture period needed and better migratory power to LN1
(1st clinical trail improved progression free survival in melanoma patients)
Problems: Semi maturen DCs unstable and can make CD4 T-cells tolerogenic and inducy CD8 T-cell immunity.

26
Q

What are the properties of tolerogenic DCs?

A

MHC II ++ , CD80/86 + , TNFalpha / IL-12 - , TGFbeta/IL-10 ++

27
Q

How can you stabilise tolDCs

A

CD14 monocytes + IL-4/GM-CSF
You then get immature DCs
Culture with IL-10 and TGF beta
Then can use Drugs such as Dex, Vit3D AND BAY11-7082

28
Q

What has TolDC induction shown in animal models?

A

Delay of Transplantation rejection and or prevntion of autoimmue diseases (autoimmune diseases can be cured)

29
Q

Work At Newcastle with tolDCs to treat RA purpose

A

re-establish tolerogenic responce against self antigen without affecting protective immunity

30
Q

Pros and conc of TolDCs for RA treatment

A

Pros: Low toxcicity, Targeted immunosuppression, Potential to restore underlying defect.
Cons: Custimised and therefor high COST, Autoantigens still not known, Risk of enhancing autoimmune responce

31
Q

What they wanted to achive with tolDC treatment forn RA

A

Presentation of self autoantigen (high signal 1)
Low co-stimulation, but this maybe needs to be changed to high (as co stimulation signal 2 needed for Treg induction)
Anti-innflammatory cytokine profile (signal 3)

32
Q

How they achived tolDCs

A

Day 0 - CD14 monocyte isolation and culture with IL-4 and GM-CSF
Day 3 - Culture of DCs with Dex, IL-4 and GM-CSF to generate immature DCs
Day 6 - Immature DC cultured with Dex, Vit3D and TLR-4 ligand
Day 7 - Mature TolDC

33
Q

What was the phenotype and cytokine profile of the TolDCs used for the RA treatment at newcastle?

A

Phenotype : MHC II +++, CD80/86 ++, CD83+/-
Cytokine Profile: IL-10+++, TGFbeta +++ , IL-12 - , IL-23/IL-6/TNF +
These DCs very good at polarising T-cells to inflammatory responce phenotype in mice.
Mice showed reduced IL-17 and Very high IL-10

34
Q

AuTo DECRA

A

Phase 1 clinical trial. Unblinded, placebo controlled dose escalation trail to assess safety, tolerability, feasibility and efficacy of biomarkers.
Conclusion - Safe (no knee flares) TolDCs local not systemic.

B-CELLS (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions